Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Ibafloxacine (R835)

Ibafloxacine (R835)

Katalog-Nr.GC33988

Ibafloxacin (R835) (R835) ist ein Fluorchinolon-Antibiotikum, das ausschließlich fÜr den veterinÄrmedizinischen Gebrauch entwickelt wurde.

Products are for research use only. Not for human use. We do not sell to patients.

Ibafloxacine (R835) Chemische Struktur

Cas No.: 91618-36-9

Größe Preis Lagerbestand Menge
1mg
717,00 $
Auf Lager
5mg
1.434,00 $
Auf Lager
10mg
2.436,00 $
Auf Lager
20mg
4.302,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ibafloxacine (R835) is a fluoroquinolone antibiotic agent that is developed exclusively for veterinary use.

The pharmacokinetic behavior of Ibafloxacin is studied after intravenous administration of a single dose of 15 mg/kg to 6 healthy lactating goats. Plasma concentrations of Ibafloxacin are determined by high-performance liquid chromatography with fluorescence detection. After IV injection Ibafloxacin shows very rapid initial distribution, with a mean half-life of 0.35 h, follows by slower elimination, with a mean half-life of 3.76 h. The elimination half-life of Ibafloxacin after oral administration has been reported to be 3.83 h in dogs and 3.00 h in cats[1].

[1]. Marín P, et al. Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats. Can J Vet Res. 2007 Jan;71(1):74-6.

Bewertungen

Review for Ibafloxacine (R835)

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ibafloxacine (R835)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.